Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

This Award Notice opportunity from Florida was posted on January 30, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

DEP 3753 ORCP CPR University of Miami CIMAS and Mote Gene Banking Weedy Coral FY 25/26

Awarded
C6667AState & Local

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.
W6QK Acc-Apg

POSTED

3 days ago

DEADLINE

N/A
NAICS: 541714
New
Federal
DNA Sequencing Service
Solicitation # 75N98027Q00090
The National Institutes of Health (NIH) is soliciting a Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract for high-throughput DNA sequencing services, including Sanger DNA sequencing and whole-plasmid sequencing. The scope of work involves processing plasmid DNA, genomic DNA, and PCR-generated material, with requirements for PCR amplification, product purification, and DNA normalization. The contractor is responsible for providing all sample collection and shipping materials, maintaining strict confidentiality of sequencing data, and retaining DNA samples for at least 180 days post-sequencing. Deliverables include specific electronic file formats such as .ab1, .fasta, and raw FASTQ data, alongside a Monthly Status Report submitted to the Contracting Officer's Representative (COR). The contract spans a five-year period from January 4, 2027, to January 3, 2032, with a total estimated value ranging from $184,200.00 to $958,584.20. Performance and delivery are centered at the NIEHS facility in Research Triangle Park, North Carolina. Award selection will be based on a best value tradeoff, where technical capability and past performance are weighted more heavily than price. Technical evaluations will focus on sequencing capability, personnel qualifications, quality assurance/control, and data management. The acquisition is not set aside for small businesses and falls under NAICS code 541714.
National Institutes Of Health Olao

POSTED

3 days ago

DEADLINE

in 17 days
NAICS: 541714
New
Federal
Presolicitation Notice to Sole Source for Experimental Pathology Laboratories, Inc. (EPL)
Solicitation # Presolicitation_NOI_Sole_Source_EPL
The U.S. Environmental Protection Agency's Office of the Chief Procurement Officer, Water, Tribal, and Science Division, intends to award a firm-fixed purchase order for histology and pathology services of maternal and neonatal rodent specimen organs. The services will be performed at the EPA Headquarters in Washington, DC, focusing on the toxicologic pathology of environmental contaminants such as PFAS, phthalates, air pollutants, and endocrine-disrupting compounds. The agency intends to sole source this requirement to Experimental Pathology Laboratories, Inc. (EPL) due to their specialized experience with EPA Quality Assurance Program requirements, compliance with Good Laboratory Practice regulations, and their ability to maintain data integrity by continuing existing studies without protocol deviations. This acquisition falls under NAICS code 541714 for Research and Development in Biotechnology and PSC code AZ11. There is no set aside used for this procurement. Responsible sources may submit capability statements, proposals, or quotations to the contracting officer by November 30, 2026, with an estimated award date of December 3, 2026. All vendors must maintain a public profile in the System for Award Management (SAM) and utilize the FedConnect portal for contract communications and documentation.
Tribal & Science Division Water

POSTED

7 days ago

DEADLINE

in 11 days

AI Contract Overview

Show more

The Department of Environmental Protection for the state of Florida has issued an award notice under solicitation number C6667A for a project titled DEP 3753 ORCP CPR University of Miami CIMAS and Mote Gene Banking Weedy Coral FY 25/26. This contract focuses on gene banking initiatives for weedy coral, involving a collaboration between the University of Miami CIMAS and Mote. The agreement is scheduled for the 2025/2026 fiscal year and was officially posted on January 30, 2026. This state-level organization effort aims to support coral preservation and research through specialized gene banking processes.

General Info

Florida DEP funds University of Miami and Mote for weedy coral gene banking.

Contract Value

$163,000

Place of Performance

FL, USA

Set-Aside

NONE

Award Issued Date

Contract End Date

June 30, 2026

Documents

0

No documents available

This contract was awarded without public documents.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

This one is closed. Find the next one like it.

Open contracts like this one, right now:

  • DNA Assay Development and Optimization SupportOpen now, due in 18 days
  • Whole-Plasmid Sequencing and Bioinformatics AssemblyOpen now, due in 18 days
See open contracts like this

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhaseAwarded
Posted

Award Notice

Awarded

Contract was awarded

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyFlorida → Department Of Environmental Protection
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
DEP 3753 ORCP CPR University of Miami CIMAS and Mote Gene Banking Weedy Coral FY 25/26

Get AI-powered intelligence on the opportunities still open

Every solicitation package arrives shredded into a compliance breakdown and matched to your past performance, with incumbent history and alerts on amendments and award.

Miguel
Hillary
Keith Deutsch
Christine

Join 900+ contractors already using CLEATUS